This work describes the clinical management and outcomes in cases of presumed infectious endophthalmitis following intravitreal injection at a tertiary academic medical center.
Methods:
A retrospective review took place of eyes that presented to the Duke Eye Center over a 9-year period and were diagnosed with intravitreal injection–related endophthalmitis. Clinical presentation, management, microbiologic yield, visual outcomes, and complications were abstracted from medical records.
Results:
Of 23 eyes diagnosed with postinjection endophthalmitis, 52.2% underwent anterior chamber tap (33.3% of which first underwent dry needle vitreous tap), 47.8% underwent needle vitreous tap, 17.4% underwent neither, and none underwent pars plana vitrectomy (PPV) for initial management. Subsequent PPV was performed in 6 eyes (26.1%). Mean visual acuity (VA) improved by 50 Early Treatment Diabetic Retinopathy Study letters at 6 months. Eyes that underwent initial anterior chamber tap had worse presenting VA than those that did not (P = .01). Eyes undergoing subsequent PPV had worse VA at presentation (P = .02) and at 6 months (P < .001). Eyes presenting with VA of hand motion (20/8000) or worse were more likely to undergo subsequent PPV (P = .02).
Conclusions:
Eyes with intravitreal injection–related endophthalmitis presenting with VA of hand motion or worse were more likely to undergo subsequent PPV. Future studies with larger cohorts may reveal whether earlier vitrectomy should be considered in these patients.
LemleyCAHanDP. Endophthalmitis: a review of current evaluation and management. Retina. 2007;27(6):662–680. doi:10.1097/IAE.0b013e3180323f96
2.
AielloLPBruckerAJChangS, et al.Evolving guidelines for intravitreous injections. Retina. 2004;24(5 suppl):S3–S19. doi:10.1097/00006982-200410001-00002
3.
FiletaJBScottIUFlynnHWJr. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014;45(2):143–149. doi:10.3928/23258160-20140306-08
4.
ReibaldiMAvitabileTBandelloF, et al.The effectiveness of 0.6% povidone iodine eye drops in reducing the conjunctival bacterial load and needle contamination in patients undergoing anti-VEGF intravitreal injection: a prospective, randomized study. J Clin Med. 2019;8(7):1031. doi:10.3390/jcm8071031
5.
RayessNRahimyEShahCP, et al.Incidence and clinical features of post-injection endophthalmitis according to diagnosis. Br J Ophthalmol. 2016;100(8):1058–1061. doi:10.1136/bjophthalmol-2015-307707
6.
JagerRDAielloLPPatelSCCunninghamETJr. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676–698. doi:10.1097/00006982-200410000-00002
7.
McCannelCA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–661. doi:10.1097/IAE.0b013e31820a67e4
8.
GragoudasESAdamisAPCunninghamETJrFeinsodMGuyerDR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805–2816. doi:10.1056/NEJMoa042760
9.
HeierJSAntoszykANPavanPR, et al.Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113(4):633.e1-e4. doi:10.1016/j.ophtha.2005.10.052
10.
StemMSRaoPLeeIJ, et al.Predictors of endophthalmitis after intravitreal injection: a multivariable analysis based on injection protocol and povidone iodine strength. Ophthalmol Retina. 2019;3(1):3–7. doi:10.1016/j.oret.2018.09.013
11.
RayessNRahimyEStoreyP, et al.Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016;165:88–93. doi:10.1016/j.ajo.2016.02.028
12.
MarkhamA. Brolucizumab: first approval. Drugs. 2019;79(18):1997–2000. doi:10.1007/s40265-019-01231-9
13.
YannuzziNAFreundKB. Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol. 2019;13:1323–1329. doi:10.2147/OPTH.S184706
14.
GreenbergJPBelinPButlerJ, et al.Aflibercept Sterile Inflammation Research Group. Aflibercept-related sterile intraocular inflammation outcomes. Ophthalmol Retina. 2019;3(9):753–759. doi:10.1016/j.oret.2019.04.006
15.
HahnPKimJEStinnettS, et al.American Society of Retina Specialists Therapeutic Surveillance Committee. Aflibercept-related sterile inflammation. Ophthalmology. 2013;120(5):1100–1101.e1-e5. doi:10.1016/j.oret.2019.04.006
16.
BaumalCRSpaideRFVajzovicL, et al.Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345–1359. doi:10.1016/j.ophtha.2020.04.017
17.
SchwartzSGFlynnHWJrEmersonGG, et al.Distinguishing between infectious endophthalmitis and noninfectious inflammation following intravitreal anti-VEGF injection. J Vitreoretinal Dis. 2019;3(1):42–44. doi:10.1177/2474126418806832
18.
SachdevaMMMoshiriALederHAScottAW. Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms. J Ophthalmic Inflamm Infect. 2016;6(1):2. doi:10.1186/s12348-015-0069-5
19.
SimonettJMIgelmanATaylorSC, et al.Culture-proven endophthalmitis after intravitreal injection: a 10-year analysis. Ophthalmic Surg Lasers Imaging Retina. 2019;50(1):33–38. doi:10.3928/23258160-20181212-05
20.
Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995;113(12):1479–1496. doi:10.1001/archopht.1995.01100120009001
21.
ChaudharyKMRomeroJMEzonIFastenbergDMDeramoVA. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection. Retina. 2013;33(7):1407–1416. doi:10.1097/IAE.0b013e3182807659
22.
ChenYShahGKShahV, et al.Outcomes and practice preferences after endophthalmitis following anti-VEGF intravitreal injection. J Vitreoretinal Dis. 2019;3(6):411–419. doi:10.1177/2474126419858492
23.
FengHLRobbinsCBFekratS. A nine-year analysis of practice patterns, microbiologic yield, and clinical outcomes in cases of presumed infectious endophthalmitis. Ophthalmol Retina. 2020;4(6):555–559. doi:10.1016/j.oret.2020.03.009
24.
CheungCSYWongAWTLuiAKertesPJDevenyiRGLamWC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609–1614. doi:10.1016/j.ophtha.2012.02.014
25.
MoshfeghiAARosenfeldPJFlynnHWJr, et al.Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011;31(4):662–668. doi:10.1097/IAE.0b013e31821067c4
26.
ShahCPGargSJVanderJFBrownGCKaiserRSHallerJA; Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028–2034. doi:10.1016/j.ophtha.2011.02.034
27.
XuKChinEKAlmeidaDRP. Variables associated with culture-positive endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors. J Vitreoretinal Dis. 2019;3(5):317–323. doi:10.1177/2474126419875652
28.
BuschCIglickiMOkadaM, et al.for the International Retina Group (IRG). Causative pathogens of endophthalmitis after intravitreal anti-VEGF injection: an international multicenter study. Ophthalmologica.2019;241(4):211–219. doi:10.1159/000496942
29.
AlBloushiAFAjamil-RodanesSTestiIWaglandCGrant-McKenzieNPavesioC. Diagnostic value of culture results from aqueous tap versus vitreous tap in cases of bacterial endophthalmitis. Br J Ophthalmol. Published online April 9, 2021. doi:10.1136/bjophthalmol-2021-318916
30.
Sjoholm-Gomez de LianoCSoberon-VenturaVFSalcedo-VillanuevaG, et al.Sensitivity, specificity and predictive values of anterior chamber tap in cases of bacterial endophthalmitis. Eye Vis (Lond). 2017;4:18. doi:10.1186/s40662-017-0083-9
31.
PatelSNStoreyPPLevinH, et al.Endophthalmitis after cataract surgery: changes in management based on microbiologic cultures. Ophthalmol Retina. 2021;5(1):16–22. doi:10.1016/j.oret.2020.06.028
32.
HoIVFernandez-SanzGLevasseurS, et al.Early pars plana vitrectomy for treatment of acute infective endophthalmitis. Asia Pac J Ophthalmol (Phila). 2019;8(1):3–7. doi:10.22608/APO.2018414
33.
PinarciEYYesilirmakNBayarSASizmazSAkkoyunIYilmazG. The results of pars plana vitrectomy and silicone oil tamponade for endophthalmitis after intravitreal injections. Int Ophthalmol. 2013;33(4):361–365. doi:10.1007/s10792-012-9702-6
34.
AgarwalAKAggarwalKSamantaR, et al.Cluster endophthalmitis due to Stenotrophomonas maltophilia following intravitreal bevacizumab: outcomes of patients from North India. Br J Ophthalmol. 2019;103(9):1278–1283. doi:10.1136/bjophthalmol-2018-313131
35.
ArtunayOYuzbasiogluERasierRSengülABahceciogluH. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond). 2009;23(12):2187–2193. doi:10.1038/eye.2009.7
36.
GoldbergRAFlynnHWJrIsomRFMillerDGonzalezS. An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):204–208.e1. doi:10.1016/j.ajo.2011.11.035
37.
PatelSNHsuJSivalingamMD, et al.Wills Post-Injection Endophthalmitis (PIE) Study Group. The impact of physician face mask use on endophthalmitis after intravitreal anti-vascular endothelial growth factor injections. Am J Ophthalmol.2020;222:194–201. doi:10.1016/j.ajo.2020.08.013
38.
HadayerAZahaviALivnyE, et al.Patients wearing face masks during intravitreal injections may be at a higher risk of endophthalmitis. Retina. 2020;40(9):1651–1656. doi:10.1097/IAE.0000000000002919
39.
RaevisJJGjyzeliGMititeluMRogersJLasarevMChangJS. Face masks and bacterial dispersion towards the periocular area. Ophthalmology. 2021;128(8):1236–1238. doi:10.1016/j.ophtha.2021.01.007
40.
PatelSNMahmoudzadehRSalabatiM, et al.Bacterial dispersion associated with various patient face mask designs during simulated intravitreal injections. Am J Ophthalmol. 2020;223:178–183. doi:10.1016/j.ajo.2020.10.017
41.
SchultheisWGSharpeJEZhangQ, et al.Effect of taping face masks on quantitative particle counts near the eye: implications for intravitreal injections in the COVID-19 era. Am J Ophthalmol. 2021;225:166–171. doi:10.1016/j.ajo.2021.01.021
